Adam D. Levy, Ph.D., MBA

Senior Vice President of Investor Relations and Corporate Communications

Adam D. Levy, Ph.D., MBA, serves as senior vice president of Investor Relations and Corporate Communications. He brings more than 20 years of experience in investor relations and corporate strategy at a variety of large and small cap biopharma companies.

Dr. Levy previously served as executive vice president, Corporate Development and Investor Relations at Ziopharm Oncology. Previously, he served as executive director, Investor Relations and head of Corporate Strategy at Gilead Sciences. He also held senior level and executive positions at Alexion, Bristol Myers Squibb, Novartis and Pfizer Animal Health (now Zoetis). Dr. Levy was also previously a consultant at McKinsey & Company, serving clients in their Healthcare practice.

He holds a B.S. degree in Genetics and a Ph.D. in Molecular Biology from the University of Illinois and an M.B.A. from the Kellogg School of Management at Northwestern University.

Turning Point Therapeutics is now a
Bristol Myers Squibb company

Select OK for information about Turning Point Therapeutics.

Select BMS to learn more about Bristol Myers Squibb